Dupilumab is a fully human monoclonal antibody inhibiting signalling of both interleukin (IL)-4 and IL-13. Dupilumab was approved by European Medical Agency (EMA) in August 2019 for adolescent aged p 12 years with moderate to severe atopic dermatitis. We report an extension analysis of a group of 139 adolescents enrolled in a previous study, beyond 16 weeks of treatment. The effectiveness of dupilumab in terms of EASI improvement according to gender, body mass index, baseline EASI, age of onset and clinical course is reported.
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis
Corazza, Monica;
2023
Abstract
Dupilumab is a fully human monoclonal antibody inhibiting signalling of both interleukin (IL)-4 and IL-13. Dupilumab was approved by European Medical Agency (EMA) in August 2019 for adolescent aged p 12 years with moderate to severe atopic dermatitis. We report an extension analysis of a group of 139 adolescents enrolled in a previous study, beyond 16 weeks of treatment. The effectiveness of dupilumab in terms of EASI improvement according to gender, body mass index, baseline EASI, age of onset and clinical course is reported.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Acad Dermatol Venereol - 2022 - Stingeni - A 52‐week update of a multicentre Italian real‐world experience on effectiveness (1).pdf
solo gestori archivio
Descrizione: versione editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
261.85 kB
Formato
Adobe PDF
|
261.85 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
